Lanair (Montelukast sodium) is a systemic maintenance medication generally used to manage specific chronic inflammatory and allergic conditions. It may be applied across domains where additional symptomatic support is needed, supporting general well-being during symptomatic phases. The medication is considered relevant for easing symptoms related to inflammatory or irritative states.

The primary therapeutic focus of Lanair involves three core areas: the prophylaxis and chronic treatment of persistent asthma, the prevention of exercise-induced bronchoconstriction (EIB), and the symptomatic relief of both seasonal and perennial allergic rhinitis.

Chronic Airway Management in Persistent Asthma

This domain covers the long-term control of chronic asthma symptoms, commonly used across conditions presenting with episodic or fluctuating manifestations such as recurrent wheezing, persistent coughing, and chest tightness. The therapy is commonly used to help with symptom clusters that may become intense or disruptive, and provides support that helps ease the overall symptom burden of chronic respiratory distress, assisting with maintaining functional stability.

Relief of Seasonal and Perennial Allergic Symptoms

The medication is commonly used to help with the symptomatic discomfort associated with allergic rhinitis, addressing both seasonal and year-round allergies. It is relevant for managing symptoms that interfere with daily comfort, such as nasal congestion, runny nose, sneezing, and watery, itchy eyes, which contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Chronic Inflammation Lanair is commonly used to manage symptoms related to inflammatory or irritative states in the airways and nasal passages. This use is relevant for conditions presenting with systemic or localized discomfort and contributes to easing bothersome allergic manifestations. It is considered relevant in situations where patients experience recurrent or chronic symptoms.

Regulatory References

1. NIH DailyMed service

Eligibility Map: Who can and cannot use Lanair — Official Regulatory Information

The eligibility for Lanair (Montelukast sodium) is strictly defined by regulatory authorities based on age, acute conditions, and known intolerances.

Populations for Whom Use is Prohibited (Contraindicated)

• Patients with a known history of mathbf hypersensitivity to Montelukast or any of its components.
• Individuals experiencing mathbf acute asthma attacks (the medicine is a maintenance therapy and not indicated for acute bronchospasm).
• Patients with specific mathbf hereditary metabolic disorders like galactose intolerance (due to excipients in some formulations).

Age-Related Eligibility Rules

The minimum age for use varies by the condition being managed:

• Adults and Adolescents: Approved for individuals mathbf15 years of age and older for all labeled uses.
• Pediatric Use Not Established: Safety and effectiveness mathbf have not been established in children below specific age cut-offs, such as mathbf12 months for asthma, and mathbf6 months for perennial allergic rhinitis.
• Older Adults: Use is permitted, and mathbf no dosage adjustment is documented as required based on age alone.

Special Population Restrictions

• Pregnancy and Lactation: Use is mathbf restricted and considered only when mathbf clearly essential due to the lack of established safety data for routine use in these groups.
• Neuropsychiatric Symptoms: Patients who develop mathbf new or worsening neuropsychiatric symptoms (e.g., agitation or depression) must mathbf discontinue treatment immediately, as required by regulatory warnings.

Interactions with other medicines and products

Lanair (Montelukast sodium) is primarily cleared from the body through metabolism involving Cytochrome P450 (CYP) enzymes, including CYP2C8, 2C9, and 3A4. Its official interaction profile is based on how co-administered drugs alter its exposure in the body.

Documented Exposure-Altering Interactions

Regulatory documents detail specific medicines that significantly affect Lanair's systemic levels:

Substance	Official Effect on Lanair Exposure
Gemfibrozil (CYP Inhibitor)	Increased Exposure: Co-administration results in an approximate 4.4-fold increase in AUC (total exposure).
Phenobarbital (CYP Inducer)	Decreased Exposure: Co-administration led to an approximate 40% decrease in AUC.
Rifampin (CYP Inducer)	May Reduce Concentration: Other potent CYP inducers may similarly decrease plasma concentrations.

Combinations with Theophylline, Prednisone, Oral Contraceptives, Digoxin, and Warfarin were found not to result in clinically significant alterations to Lanair's pharmacokinetics.

Food and Population Notes

The co-administration of the oral granule formulation with a high-fat meal results in a 35% decrease in the maximum concentration (Cmax), although the overall exposure (AUC) is unchanged. In terms of population, patients with mild-to-moderate hepatic impairment show reduced metabolism, resulting in approximately 41% higher mean AUC. Additionally, the chewable tablet formulation contains phenylalanine (aspartame), a mandatory caution for patients with Phenylketonuria (PKU). The only combination classified as strictly contraindicated is in patients with known hypersensitivity to any component of the product.

The mechanism of Lanair involves interaction with a specific component of the leukotriene signaling cascade. The mechanism is defined by the antagonism of specific leukotriene receptors within the respiratory system.

Selective Antagonism of the Leukotriene Receptor (CysLT1)

The mechanism begins at the molecular level with the selective, high-affinity antagonism of the Cysteinyl Leukotriene Receptor Type 1 (CysLT1). The active ingredient binds to and occupies this receptor, preventing the binding and signal initiation by the endogenous cysteinyl leukotrienes (LTD4, LTC4, LTE4). This targeted blockade suppresses the signal transduction that drives smooth muscle cell contraction and alters microvascular permeability in the airway lining.

Modulating Airway Inflammatory Cascades

The CysLT1 receptor blockade influences downstream processes associated with tissue inflammation. This interaction affects the recruitment and activation of inflammatory cells, such as eosinophils and mast cells, and affects leukotriene-mediated microvascular leakage and fluid accumulation (edema). The mechanistic consequence is the functional inhibition of bronchoconstriction and a decrease in airway hyperresponsiveness.

Lanair is utilized exclusively through the oral route of administration for systemic delivery. It is supplied in multiple forms, including a 10 mg film-coated tablet, 5 mg and 4 mg chewable tablets, and a 4 mg oral granule presentation, allowing for precise dosing across various age groups. The medicine is designated for chronic maintenance and is generally administered once daily.

Official Dosing and Timing

For patients receiving chronic therapy, the dose must be taken in the evening. The medicine can be taken with or without food for all dosage forms. The standard daily dose for adults and adolescents 15 years and older is 10 mg. Pediatric patients follow specific, age-dependent regimens: 5 mg once daily for those 6 to 14 years of age, and 4 mg once daily for children 2 to 5 years of age.

A separate protocol exists for prevention of exercise-induced bronchoconstriction, requiring a single dose taken at least two hours prior to activity; patients already on a daily dose must not take an additional preventative dose for this purpose. If a dose is missed, the patient should skip the missed dose and resume the regular schedule, without taking double the amount.

Granule Administration Rules

The 4 mg oral granules require specific handling: the contents of the packet must be administered within 15 minutes of opening. They can be mixed only with a spoonful of breast milk, baby formula, or specific soft foods, such as applesauce or rice. The resulting mixture must not be stored.

Research Evidence / Overview of Studies for Lanair

Evidence for Use in Chronic Treatment of Persistent Asthma

Research has explored how Lanair was observed in studies used in research exploring how symptoms evolved in the observed populations in conditions characterized by fluctuating or episodic manifestations. These studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Much of this research was applied in studies examining patient-reported experiences and studies conducted during periods of increased symptom activity. The findings describe patterns observed in the studies related to changes in outcomes reflecting daily functioning or activity level. Specifically, the data show patterns related to the way outcomes describing episodic or acute changes were observed to change during the study period.

Evidence for Use in the Prevention of Exercise-Induced Bronchoconstriction (EIB)

This research primarily used acute, randomized, controlled challenge trials that monitored the maximum drop in pulmonary function following physical activity. The outcomes measured also included the time required for function to return to baseline. The findings were recorded based on both single-dose and chronic administration schedules. This structural evidence is based on specialized, focused study designs, and studies reported consistency in observed patterns.

Evidence for Use in Symptomatic Relief of Allergic Rhinitis

Lanair was studied for its application in conditions presenting with cycles of stability and flare-ups. The studies monitored outcomes capturing phases of heightened symptom activity, which was applied in research contexts involving fluctuating or unstable symptoms. The studies report how symptoms evolved in the observed populations, and the research highlights changes measured during the study period concerning outcomes monitoring physiological strain or stress.

Long-Term Evidence and Durability of Response

Research has explored follow-up beyond the typical short-term trial period. While intermediate data was observed in some studies, the full long-term effects are not fully established. For maintenance use, there is limited information for long-term outcomes regarding the sustained effects of daily administration. Follow-up durations were limited in many of the initial trials for specific applications.

Evidence in Pediatric and Other Study Populations

Lanair was evaluated in broad age ranges, including pediatric patients (as young as 6 months for some conditions) and adolescents. Data for certain groups remain insufficient regarding older adults or those with specific comorbidities. Subgroup findings are uncertain in contexts where specific comparisons were not the primary focus of the trials. It is important to remember that the results apply only to the populations studied.

Research Gaps and Areas of Uncertainty

This final part summarizes limitations documented in scientific literature. Evidence quality varies across studies, and sample sizes were modest across a few key studies observing responses over defined time intervals. Comparative evidence is lacking in some contexts, particularly against other available approaches. Individual patient responses may vary, and the research is ongoing to fully address these areas.

Key Studies & References Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis

Common questions about Lanair (FAQ)

Q: How quickly does Lanair start working?

Clinical data suggests that symptom relief may begin within 30 minutes to an hour after the first dose. However, individual response can vary, and individuals may notice the full effect after a few days of consistent use.

It is important to follow the treatment plan set by your physician. If no improvement is noted after one week, it is important to consult a healthcare provider for further guidance.

Q: Is it safe to drink alcohol while taking Lanair?

Official prescribing information generally advises against the use of alcohol with Lanair.

The combination of alcohol and Lanair may increase the risk of certain side effects, such as dizziness or potential liver-related issues. Consulting a healthcare provider is recommended to discuss alcohol consumption while taking this medication, as the label suggests caution.

Q: Can I stop taking Lanair once my symptoms improve?

It is important to follow the full treatment duration as prescribed by a healthcare professional, even if symptoms begin to improve. Discontinuance earlier than advised may increase the likelihood of symptoms returning.

Also, a sudden change in the dose, including stopping the medication, may lead to withdrawal effects. Always consult with your healthcare provider prior to adjusting or stopping the medication.

How to Store and Dispose of Lanair?

Storage Requirements

Lanair (Montelukast sodium) must be stored under controlled conditions to maintain its stability and effectiveness. The medication should be kept at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is mandatory that the product be protected from light and moisture, and it must be stored in its original container.

Handling and Safety

Official labeling specifies that Lanair must be stored out of the sight and reach of children to prevent accidental ingestion. For oral granules, the contents of the packet require immediate administration within 15 minutes of opening to preserve stability.

Disposal Instructions

Unused or expired Lanair must be disposed of in accordance with local regulatory requirements. The medication must not be discarded in wastewater or general household trash to prevent environmental contamination.